Replies to post #181001 on Biotech Values

[DewDiligence]

PTLA’s phase-3 Betrixaban study passes futility test:

http://finance.yahoo.com/news/portolas-factor-xa-inhibitor-betrixaban-210654904.html

I don’t like the odds of success for this program for the reason mentioned in #msg-105048954 as well as my skepticism that Betrixaban is genuinely differentiated from the FXa inhibitors that failed in the indication being studied (VTE prevention in immobilized patients).

[DewDiligence]

PTLA -28%/AH on Betrixaban failure in APEX study (as I predicted on numerous occasions):

http://finance.yahoo.com/news/portola-pharmaceuticals-announces-topline-results-110000380.html

PTLA’s contention that Betrixaban was “uniquely suited” to treat patients in this indication, where other FXa inhibitors had failed, never rang true, IMO.

Moreover, there was a pretty big red flag in the APEX trial design, as noted in #msg-105048954.

CC at 8:30am ET.